euronewsGlaxo heart drug that failed trial shows potential benefitReutersWASHINGTON (Reuters) – A new type of heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial’s co-leader said.GlaxoSmithKline’s darapladib team finds hope in a PhIII bombFierceBiotechall 5 news articles …Read Full Story
Glaxo heart drug that failed trial shows potential benefit - Reuters
Real Estate of Cebu
